Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Healthcare Industry News Cesarean babies have higher at risk of obesity says new research Researchers from Johns Hopkins University in Maryland have revealed that children born through cesarean section have more risk… bypharmanewsdailyNovember 23, 2016
